Navigator Medicines, Inc.
↗Scotch Plains, New Jersey, USA
Navigator Medicines is a clinical-stage biotechnology company founded in 2024 as a subsidiary of Sera Medicines, leading the advancement of biologics for targeted immune regulation and restoration. Specializing in bispecific antibodies for complex autoimmune diseases and inflammatory disorders, Navigator acquired a pipeline of OX40L-targeted mono- and bispecific antibody candidates from South Korean biotech IMBiologics. The company's lead program, NAV-240, is a best-in-class bispecific antibody simultaneously targeting OX40L and TNFα—two clinically-validated targets in hidradenitis suppurativa, Crohn's disease, ulcerative colitis, and other difficult-to-treat inflammatory conditions. Navigator's platform addresses significant unmet medical needs in autoimmune disease treatment with potentially superior therapeutic effects compared to existing standard-of-care therapies like TNF inhibitors.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immunology, Autoimmune Therapeutics
SIZE & FINANCIALS
Employees:51-200
Revenue:Pre-commercial
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$100M+
Investors:RA Capital Management, Forbion, Sera Medicines (parent company)
PIPELINE
Stage:Phase 2a (NAV-240), Phase 1 (NAV-242)
Lead Drug Stage:Phase 2a
Modalities:Bispecific Antibodies (bsAb), mAb - Monoclonal Antibodies
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Sera Medicines, LLC
Key Partnerships:IMBiologics (drug licensing partnership, $20M upfront + $924.7M milestones), Y-Biologics (manufacturing/CDMO partner implied), Huadong Medicine (Asia-Pacific licensing implied from IMBiologics agreement)
COMPETITION
Position:Emerging
Competitors:Sanofi (KY1005/SAR445229 from Kymab acquisition, Phase 2 OX40L antibody; SAR442970 TNFα/OX40L bispecific), Amgen (entered OX40/OX40L space June 2024), Conventional TNF inhibitors (Humira/AbbVie - benchmark)
LEADERSHIP
Key Executives:
Tausif 'Tosh' Butt - Chief Executive Officer
Khurem Farooq - Chairman of the Board
Lisa Crockett - Vice President, Regulatory Affairs and Quality
William Bonificio - Co-Founder, Chief Business Officer
Board Members:Khurem Farooq (Chairman), Tausif 'Tosh' Butt (CEO), Wouter Joustra (Forbion General Partner), Andrew Levin (RA Capital Management Managing Director)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Navigator Medicines, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Navigator Medicines, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.